Davide Racaniello
Overview
Explore the profile of Davide Racaniello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
52
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volpe S, Vozza A, Lisco G, Fanelli M, Racaniello D, Bergamasco A, et al.
Nutrients
. 2024 Nov;
16(22).
PMID: 39599627
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) induce body weight loss, but their effect on skeletal muscle mass (SMM) and strength needs to be better elucidated. Objectives: This study aimed to...
2.
Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, et al.
Front Endocrinol (Lausanne)
. 2023 Oct;
14:1240263.
PMID: 37780624
Background: Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) designed for oral administration; it offers a promising opportunity to facilitate an early approach to Type 2 Diabetes (T2D)....
3.
Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, et al.
Nutrients
. 2022 Nov;
14(21).
PMID: 36364937
Background: Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting...
4.
Volpe S, Lisco G, Racaniello D, Fanelli M, Colaianni V, Vozza A, et al.
Nutrients
. 2022 Jun;
14(12).
PMID: 35745144
Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition...